Stocktoria
SCYNEXIS INC SCYX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-05-02
SCYNEXIS INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -78.0% | -990.8% | 51.9% | -1684.5% | -462.2% |
| Net margin | -41.8% | -568.3% | 47.8% | -1233.7% | -249.7% |
| FCF margin | — | — | — | — | -414.5% |
| Return on assets | -14.6% | -23.5% | 52.2% | -71.5% | -27.4% |
| Return on equity | -17.4% | -38.7% | 91.9% | -1942.7% | -79.7% |
| Debt / equity | — | — | — | — | 0.83× |
| Current ratio | 7.04 | 3.00 | 6.26 | 4.49 | 8.03 |
| Revenue growth | 449.9% | -97.3% | 2652.7% | -61.3% | — |
Source: SEC EDGAR filings · CIK 0001178253 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.